Preparation for the Commercialization and Sale of Laminin-511-E8 as a Raw Material for Research-Use Reagents
First written in FY2017-Q1. 9 of 14 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-08-07.
3 other companies' latest entry also says "Advanced".
- 2026-08-07AdvancedEarnings
「Revenue from this service increased year on year, owing to higher sales of human-type collagen and antibodies to major diagnostics manufacturers.」
Revenue from the TG silkworm service increased due to higher sales of human-type collagen and antibodies to major diagnostics manufacturers. - FY2026AdvancedAnnual report
「Revenue from this service increased year on year, as sales of NeoSilk® human-type collagen I grew, and sales of laminin-511-E8 (iMatrix-511 silk) and antibody contract services for a major in vitro diagnostics company were recorded as scheduled.」
Revenue from the TG silkworm service increased from ¥84.945 million in the previous year to ¥102.806 million, reflecting revenue from sales of Neosilk Human Collagen Type I, Laminin-511-E8 and antibody contract services. - 2026-05-13AdvancedRevision of earnings forecasts
「Revenue from this service increased year on year, as sales of NeoSilk® human-type collagen I grew, and sales of laminin-511-E8 (iMatrix-511 silk) and antibody contract services for a major in vitro diagnostics company were recorded as scheduled.」
The TG silkworm service grew on the booking of sales of NeoSilk human-type collagen I, laminin-511-E8, and antibody contract services. - FY2026-H1AdvancedAnnual report
「Revenue from this service increased 10.1% year on year to ¥52.768 million, as sales of Laminin-511-E8 (iMatrix-511 silk) and Neosilk®-Human Collagen Type I increased.」
Revenue from the TG silkworm service increased 10.1% year on year to ¥52.768 million, driven by higher sales of Laminin-511-E8 and Neosilk Human Collagen Type I. - FY2024AdvancedAnnual report
「Revenue from this service increased year on year, reflecting a substantial sale of Laminin (iMatrix-511) and revenue from antibody contract services for a major in-vitro diagnostic company.」
The TG silkworm service recorded a substantial Laminin (iMatrix-511) sale, resulting in revenue above the previous year. - FY2024-Q2AdvancedAnnual report
「Sales increased year on year due to a substantial Laminin (iMatrix-511) order.」
Laminin (iMatrix-511) benefited from a substantial order and exceeded the previous year. This marked an improvement from the decline in sales in the previous quarter. - FY2024-Q1WorsenedAnnual report
「Sales of Laminin (iMatrix-511) declined, resulting in sales below the previous year.」
Sales of Laminin-511-E8 (iMatrix-511) declined, falling below the previous year. - FY2019RestatedAnnual report
「Laminin-511-E8 (iMatrix-511 silk), produced using genetically modified silkworms, is being used by many researchers because of its functional and price advantages.」
Sales of Laminin-511-E8 as a research reagent and its use by researchers continue to expand. - FY2019-Q3RestatedAnnual report
「In this business, in addition to contract sales of antibodies and other products, Laminin-511-E8, which is useful as a culture substrate for iPS cells and other cells, is gradually gaining recognition and sales have begun to increase.」
The company continues to state that awareness of Laminin-511-E8 has increased and sales have begun to grow. - FY2019-Q2AdvancedAnnual report
「In this business, in addition to contract sales of antibodies and other products, Laminin-511-E8, which is useful as a culture substrate for iPS cells and other cells, is gradually gaining recognition and sales have begun to increase.」
The company stated that awareness of Laminin-511-E8 had increased and sales had begun to grow. Sales as a research reagent are beginning to gain market traction. - FY2018-Q1AdvancedAnnual report
「Laminin-511-E8, a fragment produced using genetically modified silkworms and effective as a culture substrate for iPS cells and other cells, has been sold generally through Nippi,Incorporated and Matrixome,Inc. since September last year. Studies are under way to scale up production and increase output.」
General sales of Laminin-511-E8 are continuing, and the company has moved on to considering scale-up to increase production. - FY2017RestatedAnnual report
「Matrixome,Inc. began selling the research reagent iMatrix-511 silk in September 2016.」
The start of Matrixome,Inc.'s sales of Laminin-511-E8 as a research reagent was reconfirmed. - FY2017-Q2AdvancedAnnual report
「We also began selling the Laminin-511-E8 fragment (Laminin-511-E8), developed through joint research with Nippi,Incorporated, as a research reagent. The fragment is effective as a culture substrate for iPS cells and other cells.」
Sales of Laminin-511-E8, developed through joint research with Nippi,Incorporated, began as a research reagent. - FY2017-Q1First statedAnnual report
「We are also preparing to sell the Laminin-511-E8 fragment (Laminin-511-E8), developed through joint research with Nippi,Incorporated, as a raw material for research reagents. The fragment is effective as a culture substrate for iPS cells and other cells.」
Preparation is under way to sell Laminin-511-E8, developed through joint research with Nippi,Incorporated, as a raw material for research reagents used as a culture substrate for iPS cells and other cells.